Estimated read time: 1-2 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
WASHINGTON, Nov 17, 2006 (UPI via COMTEX) -- The U.S. Food and Drug Administration said it will give a priority review of the breast cancer pill Tykerb, meaning a decision could be made in six months.
Pharmaceutical giant GlaxoSmithKline PLC said Tykerb, an oral cancer treatment, was filed for approval in the United States in September. A priority review by the FDA means a decision will be reached within six months of submission.
Glaxo, saying it hopes Tykerb becomes a major oncology force, seeks approval to market Tykerb as a treatment in combination with Xeloda from Roche for breast cancer that has spread to other parts of the body, The Wall Street Journal said Friday.
Some analysts said they believe Tykerb could be a $4-billion-a-year seller but this would depend on its competing against Herceptin, an injected drug from Roche and Genentech used in early stage cancer.
URL: www.upi.com Copyright 2006 by United Press International **********************************************************************
As of Monday, 11-13-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 10-30-2006 for GSK @ $53.18.
For more information on Comtex SmarTrend® Alert, contact your market data provider or go to www.CSTADirect.com
SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright © 2004-2006 Comtex News Network, Inc. All Rights Reserved.
